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344Background: A competent aortic valve is essential to providing effective left ventricular assist device support.
We have adopted a practice of central aortic valve closure by placing a simple coaptation stitch at left ventricular
assist device implantation in patients with significant aortic insufficiency. We conducted a follow-up study to
evaluate the efficacy and durability of this procedure.
Methods: The study included patients who had undergone continuous flow left ventricular assist device implan-
tation. The patients were divided into 2 groups, those who did not require any aortic procedure because the valve
was competent and those who underwent central aortic valve closure for mild or greater aortic regurgitation. The
clinical endpointsweremortality, progression or recurrence of aortic insufficiency, and reoperation for aortic valve
pathologic features. Aortic insufficiency was measured qualitatively from mild to severe on a scale of 0 to 5.
Results: A total of 123 patients received continuous flow left ventricular assist devices from February 2007 to
August 2011. Of those, 18 (15%) underwent central aortic valve closure at left ventricular assist device implan-
tation because of significant aortic insufficiency (1.8 1.4) and 105 who did not (competent aortic valve, 0.15
0.43; P< .01). At follow-up (median, 312 days; range, 0-1429 days), the mean aortic insufficiency score
remained low for the patients with central aortic valve closure (0.27  0.46) in contrast to those without central
aortic valve closure who experienced aortic insufficiency progression (0.78  0.89; P ¼ .02). In addition, the
proportion of patients with more than mild aortic insufficiency was significantly less in the central aortic valve
closure group (0% vs 18%; P ¼ .05). The patients in the central aortic valve closure group were significantly
older and had a greater incidence of renal failure at baseline. The 30-day mortality was greater in the central
aortic valve closure group, but the late survival was similar between the 2 groups. No reoperations were required
for recurrent aortic insufficiency.
Conclusions: The results of our study have shown that repair of aortic insufficiency with a simple central
coaptation stitch is effective and durable in left ventricular assist device-supported patients, with follow-up
extending into 2 years. Although aortic insufficiency progressed over time in those with minimal native valve
regurgitation initially, no such progression was noted in those with central aortic valve closure. Additional in-
vestigation is needed to evaluate whether prophylactic central aortic valve closure should be performed at left
ventricular assist device implantation to avoid problematic aortic regurgitation developing over time, in partic-
ular in patients undergoing left ventricular assist device implantation for life-long (destination therapy) support.
(J Thorac Cardiovasc Surg 2014;147:344-8)A competent aortic valve is essential for optimal hemody-
namics in patients with left ventricular assist devices
(LVADs) to allow forward, and not ineffective, circular,
systemic blood flow.1 Several methods are available for
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The Journal of Thoracic and Cardiovascular Surgvalve replacement,2 patch closure of the aortic root,3 com-
plete aortic valve closure,4 and central aortic valve closure
(CAVC), consisting of partial closure of the aortic valve
cusps, reported as Park’s stitch.5 CAVC has the potential
to be the ideal technique, because it is inexpensive, quick,
and simple to perform and might not have the same degen-
erative potential as biologic valve prostheses. Although the
short-term durability of CAVC has been described in pa-
tients receiving pulsatile LVADs, its efficacy in nonpulsatile
LVADs and its long-term durability are unknown.We, there-
fore, reviewed our experience of CAVC in patients receiving
nonpulsatile LVADs to evaluate its efficacy and durability.METHODS
The institutional review board approved our research involving human
subjects. The need for written informed consent was waived owing to the
minimal risk nature of the present study, but all patients had given consentery c January 2014
Abbreviations and Acronyms
AI ¼ aortic insufficiency
CAVC ¼ central aortic valve closure
LVAD ¼ left ventricular assist device
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tronic LVAD database and through our institution’s electronic medical
record, which includes all inpatient, outpatient, and imaging records. The
study group consisted of patients who had undergone CAVC and the
control group consisted of patients who had not. During the same period,
7 patients underwent aortic valve replacement for aortic valve repeat
replacement of amechanical valve prosthesis or suture closure of amechan-
ical valve prosthesis. Because our clinical question was the durability of the
central coaptation stitch (not a comparison of various techniques), these 7
patients were excluded from the present analysis.
The primary endpoint of the present study was the durability of CAVC
as assessed by echocardiography, as described previously.6 The baseline
assessment of AI was ascertained by preoperative surface and intraopera-
tive transesophageal echocardiography. Postoperative echocardiography
was performed monthly and as needed in our LVAD population, usually
monthly. The degree of AI was qualitatively scored on a 5-point scale as
follows: 0, none; 1, mild; 2, mild-to-moderate; 3, moderate; 4, moderate-
to-severe; and 5, severe. This corresponds to the American Society of
Echocardiography7 standards of none (Mayo score, 0), mild (Mayo score,
1), moderate (Mayo score, 3), and severe (Mayo score, 5). We categorized
the patients by the indication for LVAD support as receiving either bridge-
to-transplant or destination therapy. The secondary end points consisted of
early (within 30 days of LVAD implant) and late mortality and the need for
reoperation for aortic regurgitation.
The technique of CAVC using a central coaptation stitch has been pre-
viously described for patients with central regurgitation of native AI.5 In
brief, after initiation of cardiopulmonary bypass, the aorta was cross-
clamped and diastolic arrest of the heart was initiated by either antegrade
or retrograde cardioplegia. An oblique aortotomy was made at the site of
the LVAD outflow graft anastomosis. The 3 aortic valve cusps were coapted
centrally with one 5-0 polypropylene monofilament suture with small felt
pledgets in each cusp (Figure 1). The aortic outflow graft was anastomosed
in the usual fashion, and the aortic crossclamp was released.
Statistical analyses were performed using JMP, version 9.0.1 (SAS In-
stitute, Cary, NC). Owing to the small sample size, nonparametric analyses
were performed. The continuous variables are presented as the mean 
standard deviation and were compared using the Kruskal-Wallis test for
heterogeneity. Categorical variables are reported as percentages and were
statistically examined using Fisher’s exact test, as appropriate.RESULTS
A total of 123 patients received continuous flow LVADs
during the study period. Of those, 18 (15%) underwent
CAVC for AI. The mean age of all patients at LVAD implant
was 60 years; however, those undergoing CAVC were older
(66  11 vs 59  14 years; P ¼ .03). The etiology of heart
failure was ischemic in just fewer than one half the patients
(47%) and did not differ between the 2 groups. The 2
groups did differ with respect to a greater incidence of
pre-existing chronic renal insufficiency and more patients
receiving LVAD therapy for destination therapy in the group
undergoing CAVC. The complete patient demographic data
are presented in Table 1.The Journal of Thoracic and CaThe CAVC group had longer cardiopulmonary bypass
times (155 61 vs 108 43; P<.01. Aortic crossclamping
was more frequent in the CAVC group (100% CAVC vs
13% no CAVC; P<.01). For those patients in both groups
who underwent aortic crossclamping (for all concomitant
procedures), however, no difference was present in the aor-
tic crossclamp time (42 vs 41 minutes, respectively;
P ¼ NS). Early survival favored those without CAVC
(97% vs 78%; P ¼ .01). However, for those who survived,
no difference was found in the length of hospital stay (23 
16 vs 26  21 days). The complete intraoperative and early
postoperative data are presented in Table 2. The early deaths
in the CAVC group consisted of 4 patients who died within
the first 17 days postoperatively. Of these 4 patients, 2 pa-
tients died of right ventricular failure and multisystem or-
gan failure on postoperative days 2 and 17. Another died
on postoperative day 4 of a cerebrovascular accident, and
fourth died of anoxic brain injury after ventricular fibrilla-
tion arrest on postoperative day 16. In all cases, the LVADs
were functioning appropriately leading up to the time of
death.
The patients undergoing CAVC had more severe AI at
LVAD implant (mean score, 1.8  1.4 vs 0.15  43;
P<.01). Immediately after LVAD placement, no patient in
either group had more than mild AI. At the last imaging
follow-up study (mean, 497days; range, 37-1596days), how-
ever, the severity of AI was significantly lower for the CAVC
group (mean score, 0.27  0.46) than for no-CAVC group
(mean score, 0.78  0.89; P ¼ .02), resulting in a mean
change in severity of AI of 1.5 compared with þ0.6 in
the no-CAVC group (P<.01). Furthermore, 18% of patients
without CAVC experienced progression of AI to more than
mild, but none in the CAVC group had greater than mild
AI at the last follow-up examination (P ¼ .05) (Table 3).
During clinical follow-up, no reoperations for recurrent AI
(after CAVC) were required in the present series, nor was
a difference in late survival found between the 2 groups.
DISCUSSION
The principal finding of the present study was that CAVC
with Park’s stitch at LVAD implantation is effective in
reducing AI and durable, with follow-up extending into 2
years. Additionally, an otherwise competent native aortic
valve can develop AI over time with LVAD support.
AI in patients requiring LVAD therapy is not uncommon,
as shown by the 15% prevalence in our series. The correc-
tion of AI at LVAD implantation has been shown to be as-
sociated with increased perioperative mortality in some,8
but not all, studies.4,9 The HeartMate II investigators
reported their experience with concomitant cardiac
operations at LVAD implantation. In their series, 47
patients underwent a valvular operation, 12 of whom
underwent an aortic valve procedure, including a few
patients (n ¼ 8) who had the aortic valve patched closedrdiovascular Surgery c Volume 147, Number 1 345
FIGURE 1. Left, Central aortic regurgitation of native aortic valve. Middle, Central coaptation stitch of aortic valve performed at left ventricular assist
device implantation. Right, Ejection of blood around centrally coapted aortic valve.
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replacement. They reported an early mortality of 25% for
patients undergoing an aortic valve procedure andTABLE 1. Patient demographics
Variable
Total
patients
(n ¼ 123)
Aortic valve repair
P
value
Yes
(n ¼ 18)
No
(n ¼ 105)
Age (y) 60  13 66  11 59  14 .03
Women (%) 16 17 16 NS
White race (%) 93 88 93 NS
Ischemic
cardiomyopathy (%)
47 50 47 NS
Hypertension (%) 34 22 36 NS
Diabetes mellitus (n) 41 (33) 5 (28) 36 (34) NS
Renal insufficiency (n) 73 (60) 15 (83) 58 (55) .04
Atrial fibrillation (n) 37 (30) 7 (39) 30 (29) NS
Redo sternotomy (n) 54 (44) 11 (61) 43 (41) NS
Left ventricular
ejection fraction (%)
20  9.3 17  5 20  10 NS
Destination therapy (n) 77 (63) 15 (83) 62 (60) .05
Severity of aortic
regurgitation
(by intraoperative
TEE)
— 1.8  1.4 0.15  0.43 <.01
Proportion of AI
greater than mild
(by intraoperative
TEE)
— 100 0
BSA (cm2) 2.04  0.24 1.96  0.05 2.05  0.24 NS
Data presented as mean  standard deviation, %, or n (%). TEE, Transesophageal
echocardiography; AI, aortic insufficiency; BSA, body surface area.
346 The Journal of Thoracic and Cardiovascular Surgtheorized that it was, in part, owing to the need for
cardioplegic arrest, with resultant myocardial dysfunction
in already-marginal hearts. Studying those early deaths
closely, sepsis and stroke was the cause of early death for
2 of the 3 patients; only 1 patient died of right ventricular
failure. Of the early and late deaths, 4 of the 5 patients
who died after an aortic valve procedure had undergone aor-
tic valve replacement, not aortic valve closure. The reported
cause of death in the remaining patient was sepsis.
In our series, we also observed greater early mortality
among patients undergoing CAVC; however, the cause of
death was also not attributable to the aortic valve procedure.
Patients in the CAVC group were, on average, older and had
more severe pre-existing comorbidities. The cause of death
was right ventricular failure for only 1 of our 4 early deaths;
the remaining 3 patients died ofmultisystem organ failure or
hypoxic cerebral complications. Additionally, our 30-day
survival for the CAVC group was not much different fromTABLE 2. Intraoperative data
Variable
Aortic valve repair P
valueYes (n ¼ 18) No (n ¼ 105)
Cardiopulmonary bypass time (min) 155  61 108  43 .004
Aortic crossclamp time (min) 42  25 41  27* NS
Tricuspid valve procedure 13 (72) 52 (50) NS
Length of hospital stay (d) 26  21 23  16 NS
30-d mortality 4 (22) 3 (3) .01
Data presented asmean standard deviation or n (%). *Of 105 patients, 14 underwent
aortic crossclamping.
ery c January 2014
TABLE 3. Clinical course of aortic regurgitation
Variable
Aortic valve repair P
valueYes (n ¼ 18) No (n ¼ 105)
Echocardiographic follow-up (d) 441  288 504  354 NS
Severity of aortic regurgitation 0.27  0.46 0.78  0.89 .02
Patients with greater than mild
regurgitation (%)
0/18 (0) 19/105 (18) .05
Data presented as mean  standard deviation or n (%).
McKellar et al Acquired Cardiovascular Disease
A
C
Dthat reported by the HeartMate II investigators (79% vs
74%). However, it was inferior to the excellent survival out-
come of 97% we observed for the patients without CAVC.8
Combined, these observations might support the theory that
the long cardioplegic arrest times required to address AI
(aortic valve replacement or CAVC) might contribute to
early mortality; however, the shorter arrest times required
for CAVC might be associated with proportionately less
risk. To explore this possibility, we studied the effect of aor-
tic crossclamping on 30-day mortality and found no associ-
ation in our patient experience (P ¼ NS; data not shown).
However, additional research is warranted in this area.
The development of native aortic valve regurgitation in pa-
tients with continuous flow LVADs is also not uncommon,
demonstrated by the 18% incidence of greater than mild AI
in our series. Numerous case reports and some case series
have also been published describing the clinical problem of
de novo AI during LVAD support.10-14 To date, 2 of our
patients required reoperation because of the development of
de novo AI after LVAD implant, and 1 died perioperatively.
Reoperation for AI in patients receiving LVAD support
can be very challenging. Recently, case reports have been
published of an alternative percutaneous approach.15 It might
prove very promising for those who develop delayed AI
during LVAD support, but the experience is rather limited.
Whether AI is an inevitable consequence of the constantly
pressurized, closed aortic valve found during continuous
flow LVAD support or whether this can be ameliorated by
allowing the aortic valve to open intermittently is a topic for
future investigation.
The limitations of the present study included those inher-
ent to any retrospective clinical study; specifically, the small
sample size and limited follow-up period. Additionally, the
follow-up imaging was limited by serial studies performed
under varying hemodynamic conditions (ie, volume status,
antihypertensive regimen). Also, potential limitations exist
to oversewing the aortic valve at LVAD implantation. One
potential concern is that of cardiovascular collapse in the set-
ting of LVAD pump failure due to complete pump thrombo-
sis. One can speculate that this would bemore likely to occur
if the entire left ventricular outflow tract is occluded by ei-
ther a thrombosed biologic valve2 or complete oversewing
of the aortic valve.4 If LVAD failurewere to occur in the set-
ting of a completely closed aortic valve, no egress of bloodThe Journal of Thoracic and Cafrom the ventriclewould be possible, prompting sudden car-
diovascular collapse. In contrast, if the aortic valve were
only centrally closed, it is theoretically possible that blood
could be ejected around the partial closure, allowing some
cardiac output. Additionally, CAVC is contraindicated for
patients in whom ventricular recovery is a possibility.
The present study was not a head-to-head comparison of
the different techniques of aortic valve closure. Some phil-
osophical differences could exist in addressing AI at LVAD
implantation. Some investigators believe that the central co-
aptation stitch we use is inadequate because of 1 HeartMate
I patient whose centrally plicated aortic valve became re-
gurgitant and required repeat repair.4 This was not observed
in our series, perhaps because our series only included con-
tinuous flow devices with different physiology and aortic
valve-loading conditions. In our experience, all patients
with CAVC were free from greater than mild AI at the
last follow-up examination. Aortic valve replacement with
a biologic aortic valve prosthesis2 or patch closure3 of the
aorta are other alternatives but not our preference,11 because
we believe the central coaptation stitch is quick and simple
to perform, with well-demonstrated efficacy and durability.CONCLUSIONS
Aortic valve repair using a central coaptation stitch is ef-
fective in reducing aortic regurgitation in patients with native
aortic valve regurgitation at LVAD implantation. It has also
proved to be durable in maintaining a competent aortic valve
during follow-up extending beyond 2 years. It is our preferred
approach to treating native aortic valve regurgitation atLVAD
implantation owing to its simplicity, efficacy, and durability.
Longer term follow-up is required to determine whether its
use is warranted prophylactically in patients with no possibil-
ity of ventricular recovery and a long anticipated duration of
LVAD support, such as permanent (destination) therapy to
reduce the incidence of de novo or progression of mild aortic
regurgitation after LVAD implantation.References
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